Skip to main content
Top
Published in: Clinical Phytoscience 1/2017

Open Access 01-12-2017 | Review

The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots: effects of extracts of chasteberry (Vitex agnus castus) as a solution

Authors: Dana Seidlova-Wuttke, Wolfgang Wuttke

Published in: Clinical Phytoscience | Issue 1/2017

Login to get access

Abstract

The dried fruits of the chaste tree Vitex agnus castus (VAC) were traditionally used by monks as a substitute for pepper and was therefore also called Monk’s pepper. For the last 50 years it is commercially provided for the treatment of premenstrual symptoms, particularly to prevent premenstrual mastodynia (mastalgia). Most studies were performed with the preparation containing an aqueous/ethanolic ectract BNO 1095. A number of placebo controlled studies gave proof that extracts of VAC had beneficial effects on premenstrual breast pain. This breast sensation is induced by latent hyperprolactinemia which is characterized by secretory episodes of prolactin release by the pituitary in response to stress and deep sleep phases. This latent hyperprolactinemia induces also often a corpus luteum insufficiency which is a common reason for infertilty.
It is well accepted that prolactin release can be reduced by dopamine and dopaminergic drugs. The efficacy of VAC extracts to ameliorate prolactin induced premenstrual mastodynia was therefore suggestive that VAC may contain dopaminergic compounds. Indeed, a number of diterpenes were identified that bound to recombinant Dopamine receptors of the 2 subtype (D2 receptors) which are present in pituitary lactotropes and which mediate the inhibitory effects of dopamine and dopaminergic drugs on pituitary prolactin release. Consequently, prolactin release in vitro from dispersed pituitary cells and in vivo in rats and postmenopausal women was inhibited by VAC 1095. Placebo controlled studies proved also the efficacy of VAC extracts to ameliorate premenstrual symptoms. In several placebo-controlled studies a clear relation between reduction of breast pain and reduction of serum prolactin levels could be established. In addition VAC extracts was also highly effective in women suffering from fibrocystic mastopathy. In many of these women serum prolactin levels were also elevated and reduced by VAC extracts.
The results from all trials suggested that VAC extracts ameliorated premenstrual symptoms including mastodynia, premenstrual dysphoric disorder and latent hyperprolactinemia. Cystic mastopathy and sterility due to corpus luteum insufficiencies were also beneficially influenced.
Adverse events with VAC were mild and generally infrequent.
Literature
1.
go back to reference Halbreich U, Ben-David M, Assael M, Bornstein R. Serum-prolatic in women with premenstrual syndrome. Lancet. 1976;2:654–6.CrossRefPubMed Halbreich U, Ben-David M, Assael M, Bornstein R. Serum-prolatic in women with premenstrual syndrome. Lancet. 1976;2:654–6.CrossRefPubMed
3.
go back to reference Schulz KD, Del Pozo E, Lose KH, Kunzig HJ, Geiger W. Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch Gynakol. 1975;220:83–7.CrossRefPubMed Schulz KD, Del Pozo E, Lose KH, Kunzig HJ, Geiger W. Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch Gynakol. 1975;220:83–7.CrossRefPubMed
4.
go back to reference Schwibbe MH. Multivariate relationship analysis of personality, speech and EEG. Z Exp Angew Psychol. 1983;30:133–52.PubMed Schwibbe MH. Multivariate relationship analysis of personality, speech and EEG. Z Exp Angew Psychol. 1983;30:133–52.PubMed
5.
go back to reference Muhlenstedt D, Bohnet HG, Hanker JP, Schneider HP. Short luteal phase and prolactin. Int J Fertil. 1978;23:213–8.PubMed Muhlenstedt D, Bohnet HG, Hanker JP, Schneider HP. Short luteal phase and prolactin. Int J Fertil. 1978;23:213–8.PubMed
6.
go back to reference del Pozo E, Wyss H, Tollis G, et al. Prolactin and deficient luteal function. Obstet Gynecol. 1979;53:282–6.PubMed del Pozo E, Wyss H, Tollis G, et al. Prolactin and deficient luteal function. Obstet Gynecol. 1979;53:282–6.PubMed
7.
go back to reference Wuttke W, Pitzel L, Seidlova-Wuttke D, Hinney B. LH pulses and the corpus luteum: the luteal phase deficiency LPD). Vitam Horm. 2001;63:131–58.CrossRefPubMed Wuttke W, Pitzel L, Seidlova-Wuttke D, Hinney B. LH pulses and the corpus luteum: the luteal phase deficiency LPD). Vitam Horm. 2001;63:131–58.CrossRefPubMed
8.
go back to reference van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79:562–75.PubMed van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79:562–75.PubMed
9.
go back to reference Wuttke W, Jarry H, Knoke I, Pitzel L, Spiess S. Luteotropic and luteolytic effects of oxytocin in the porcine corpus luteum. Adv Exp Med Biol. 1995;395:495–506.PubMed Wuttke W, Jarry H, Knoke I, Pitzel L, Spiess S. Luteotropic and luteolytic effects of oxytocin in the porcine corpus luteum. Adv Exp Med Biol. 1995;395:495–506.PubMed
10.
go back to reference Wuttke W, Duker EM, Demajo M, Mansky T, Lira S. Postnatal development of hypothalamic neurotransmitters. Monogr Neural Sci. 1983;9:225–33.PubMed Wuttke W, Duker EM, Demajo M, Mansky T, Lira S. Postnatal development of hypothalamic neurotransmitters. Monogr Neural Sci. 1983;9:225–33.PubMed
11.
go back to reference Guy PL, Webster DE, Davis L, Forster RL. Pests of non-indigenous organisms: Hidden costs of introduction. Trends Ecol Evol. 1998;13:111.CrossRefPubMed Guy PL, Webster DE, Davis L, Forster RL. Pests of non-indigenous organisms: Hidden costs of introduction. Trends Ecol Evol. 1998;13:111.CrossRefPubMed
12.
go back to reference Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med. 2003;69:945–7.CrossRefPubMed Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med. 2003;69:945–7.CrossRefPubMed
13.
go back to reference Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine. 2004;11:18–23.CrossRefPubMed Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine. 2004;11:18–23.CrossRefPubMed
14.
15.
go back to reference Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102:448–54.CrossRefPubMed Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102:448–54.CrossRefPubMed
16.
go back to reference Meier B, Berger D, Hoberg E, Sticher O, Schaffner W. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine. 2000;7:373–81.CrossRefPubMed Meier B, Berger D, Hoberg E, Sticher O, Schaffner W. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine. 2000;7:373–81.CrossRefPubMed
17.
go back to reference Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10:348–57.CrossRefPubMed Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10:348–57.CrossRefPubMed
18.
go back to reference Chen SN, Friesen JB, Webster D, et al. Phytoconstituents from Vitex agnus-castus fruits. Fitoterapia. 2011;82:528–33.CrossRefPubMed Chen SN, Friesen JB, Webster D, et al. Phytoconstituents from Vitex agnus-castus fruits. Fitoterapia. 2011;82:528–33.CrossRefPubMed
19.
go back to reference Webster DE, He Y, Chen SN, et al. Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol. 2011;81:170–7.CrossRefPubMed Webster DE, He Y, Chen SN, et al. Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol. 2011;81:170–7.CrossRefPubMed
20.
go back to reference Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung. 1993;43:752–6.PubMed Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung. 1993;43:752–6.PubMed
21.
go back to reference Mayerhofer A, Fritz S, Grunert R, et al. D1-Receptor, DARPP-32, and PP-1 in the primate corpus luteum and luteinized granulosa cells: evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin. J Clin Endocrinol Metab. 2000;85:4750–7.CrossRefPubMed Mayerhofer A, Fritz S, Grunert R, et al. D1-Receptor, DARPP-32, and PP-1 in the primate corpus luteum and luteinized granulosa cells: evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin. J Clin Endocrinol Metab. 2000;85:4750–7.CrossRefPubMed
22.
go back to reference Mayerhofer A, Hemmings Jr HC, Snyder GL, et al. Functional dopamine-1 receptors and DARPP-32 are expressed in human ovary and granulosa luteal cells in vitro. J Clin Endocrinol Metab. 1999;84:257–64.PubMed Mayerhofer A, Hemmings Jr HC, Snyder GL, et al. Functional dopamine-1 receptors and DARPP-32 are expressed in human ovary and granulosa luteal cells in vitro. J Clin Endocrinol Metab. 1999;84:257–64.PubMed
24.
go back to reference Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol. 1986;154:161–79.CrossRefPubMed Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol. 1986;154:161–79.CrossRefPubMed
25.
go back to reference Murta EF, de Freitas MM, Velludo MA. Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine. Rev Paul Med. 1992;110:251–6.PubMed Murta EF, de Freitas MM, Velludo MA. Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine. Rev Paul Med. 1992;110:251–6.PubMed
26.
go back to reference Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005;10:325–35.CrossRefPubMed Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005;10:325–35.CrossRefPubMed
27.
go back to reference Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev. 1992;16:67–72.PubMed Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev. 1992;16:67–72.PubMed
28.
go back to reference Ho JM, Jafferjee N, Covarrubias GM, Ghesani M, Handler B. Dense breasts: a review of reporting legislation and available supplemental screening options. AJR Am J Roentgenol. 2014;203:449–56.CrossRefPubMed Ho JM, Jafferjee N, Covarrubias GM, Ghesani M, Handler B. Dense breasts: a review of reporting legislation and available supplemental screening options. AJR Am J Roentgenol. 2014;203:449–56.CrossRefPubMed
29.
go back to reference Walker K, Fletcher O, Johnson N, et al. Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res. 2009;69:6490–9.CrossRefPubMed Walker K, Fletcher O, Johnson N, et al. Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res. 2009;69:6490–9.CrossRefPubMed
30.
go back to reference Laud K, Gourdou I, Belair L, Peyrat JP, Djiane J. Characterization and modulation of a prolactin receptor mRNA isoform in normal and tumoral human breast tissues. Int J Cancer. 2000;85:771–6.CrossRefPubMed Laud K, Gourdou I, Belair L, Peyrat JP, Djiane J. Characterization and modulation of a prolactin receptor mRNA isoform in normal and tumoral human breast tissues. Int J Cancer. 2000;85:771–6.CrossRefPubMed
31.
go back to reference Courtillot C, Chakhtoura Z, Bogorad R, et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab. 2010;95:271–9.CrossRefPubMed Courtillot C, Chakhtoura Z, Bogorad R, et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J Clin Endocrinol Metab. 2010;95:271–9.CrossRefPubMed
32.
go back to reference Sirotkovic-Skerlev M, Cacev T, Krizanac S, et al. TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol. 2007;83:54–8.CrossRefPubMed Sirotkovic-Skerlev M, Cacev T, Krizanac S, et al. TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol. 2007;83:54–8.CrossRefPubMed
33.
go back to reference Bhargav PR, Mishra A, Agarwal G, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33:2087–93.CrossRefPubMed Bhargav PR, Mishra A, Agarwal G, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33:2087–93.CrossRefPubMed
34.
go back to reference Bazyka DA, Lytvynenko O, Bugaistov S. Structural and functional thyroid abnormalities in patients with dyshormonal breast disorders and tumors. Probl Radiac Med Radiobiol. 2013;18:156–68. Bazyka DA, Lytvynenko O, Bugaistov S. Structural and functional thyroid abnormalities in patients with dyshormonal breast disorders and tumors. Probl Radiac Med Radiobiol. 2013;18:156–68.
35.
go back to reference Adashi EY, Katz E. Diagnostic work-up of hyperprolactinemic disorders. Gynecol Endocrinol. 1988;2:339–57.CrossRefPubMed Adashi EY, Katz E. Diagnostic work-up of hyperprolactinemic disorders. Gynecol Endocrinol. 1988;2:339–57.CrossRefPubMed
36.
go back to reference McCann SM, Ono N, Khorram O, Kentroti S, Aguila C. The role of brain peptides in neuroimmunomodulation. Ann N Y Acad Sci. 1987;496:173–81.CrossRefPubMed McCann SM, Ono N, Khorram O, Kentroti S, Aguila C. The role of brain peptides in neuroimmunomodulation. Ann N Y Acad Sci. 1987;496:173–81.CrossRefPubMed
37.
38.
go back to reference Korbonits M, Morris DG, Nanzer A, Kola B, Grossman AB. Role of regulatory factors in pituitary tumour formation. Front Horm Res. 2004;32:63–95.CrossRefPubMed Korbonits M, Morris DG, Nanzer A, Kola B, Grossman AB. Role of regulatory factors in pituitary tumour formation. Front Horm Res. 2004;32:63–95.CrossRefPubMed
39.
go back to reference Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol. 2010;22:771–7.PubMed Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol. 2010;22:771–7.PubMed
40.
go back to reference Meites J, Lu KH, Wuttke W, et al. Recent studies on functions and control of prolactin secretion in rats. Recent Prog Horm Res. 1972;28:471–526.PubMed Meites J, Lu KH, Wuttke W, et al. Recent studies on functions and control of prolactin secretion in rats. Recent Prog Horm Res. 1972;28:471–526.PubMed
41.
go back to reference Damiano JS, Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res. 2013;19:1644–50.CrossRefPubMed Damiano JS, Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res. 2013;19:1644–50.CrossRefPubMed
42.
go back to reference Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998;83:667–74.CrossRefPubMed Touraine P, Martini JF, Zafrani B, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998;83:667–74.CrossRefPubMed
43.
go back to reference Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25:1482–8.CrossRefPubMed Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25:1482–8.CrossRefPubMed
44.
go back to reference Tikk K, Sookthai D, Johnson T, et al. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol. 2014;25:1422–8.CrossRefPubMed Tikk K, Sookthai D, Johnson T, et al. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol. 2014;25:1422–8.CrossRefPubMed
45.
go back to reference Gumenyuk, EG. Some problems of premenstrual syndrome and alternative therapy. Jounal of Obstetrics and gynecological diseases. 2010;:38-45. Gumenyuk, EG. Some problems of premenstrual syndrome and alternative therapy. Jounal of Obstetrics and gynecological diseases. 2010;:38-45.
46.
go back to reference Binita G, Suprava P, Mainak C, Koner BC, Alpana S. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J Reprod Infertil. 2009;10:207–12.PubMed Binita G, Suprava P, Mainak C, Koner BC, Alpana S. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J Reprod Infertil. 2009;10:207–12.PubMed
Metadata
Title
The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots: effects of extracts of chasteberry (Vitex agnus castus) as a solution
Authors
Dana Seidlova-Wuttke
Wolfgang Wuttke
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Phytoscience / Issue 1/2017
Electronic ISSN: 2199-1197
DOI
https://doi.org/10.1186/s40816-016-0038-z

Other articles of this Issue 1/2017

Clinical Phytoscience 1/2017 Go to the issue